- Report
- May 2026
- 142 Pages
Global
From €2687EUR$2,999USD£2,302GBP
€3583EUR$3,999USD£3,069GBP
- Report
- June 2026
- 182 Pages
Global
From €3176EUR$3,545USD£2,721GBP
€3529EUR$3,939USD£3,023GBP
- Report
- August 2026
- 283 Pages
Global
From €5242EUR$5,850USD£4,490GBP
- Report
- July 2026
- 188 Pages
Global
From €3176EUR$3,545USD£2,721GBP
€3529EUR$3,939USD£3,023GBP
- Report
- July 2026
- 198 Pages
Global
From €3176EUR$3,545USD£2,721GBP
€3529EUR$3,939USD£3,023GBP
- Report
- June 2026
- 193 Pages
Global
From €3176EUR$3,545USD£2,721GBP
€3529EUR$3,939USD£3,023GBP
- Report
- June 2026
- 198 Pages
Global
From €3176EUR$3,545USD£2,721GBP
€3529EUR$3,939USD£3,023GBP
- Report
- January 2026
- 185 Pages
Global
From €4032EUR$4,500USD£3,454GBP
- Report
- February 2026
- 250 Pages
Global
From €4023EUR$4,490USD£3,446GBP
- Report
- August 2026
- 213 Pages
Global
From €5242EUR$5,850USD£4,490GBP
- Report
- August 2026
- 252 Pages
Global
From €5242EUR$5,850USD£4,490GBP
- Report
- July 2026
- 135 Pages
Global
From €4256EUR$4,750USD£3,646GBP
- Report
- January 2026
- 150 Pages
Global
From €4346EUR$4,850USD£3,722GBP
- Report
- February 2024
- 72 Pages
South Korea
From €4480EUR$5,000USD£3,838GBP
- Report
- August 2023
- 1500 Pages
Global
From €7840EUR$8,750USD£6,716GBP
- Report
- January 2023
- 195 Pages
Latin America
From €4480EUR$5,000USD£3,838GBP
- Report
- June 2022
- 55 Pages
India
From €4480EUR$5,000USD£3,838GBP
- Report
- June 2021
- 197 Pages
Latin America
From €3584EUR$4,000USD£3,070GBP
- Report
- October 2023
- 253 Pages
Global
From €4435EUR$4,950USD£3,799GBP
- Report
- January 2025
- 183 Pages
Global
From €4032EUR$4,500USD£3,454GBP

The NAT Screening market within the context of In Vitro Diagnostics is a segment of the healthcare industry that focuses on the development and commercialization of tests that detect the presence of infectious agents in a sample. These tests are used to diagnose and monitor the spread of infectious diseases, such as HIV, hepatitis, and other viruses. NAT Screening tests are used in a variety of settings, including clinical laboratories, hospitals, and public health departments.
NAT Screening tests are typically performed using a variety of technologies, such as polymerase chain reaction (PCR), nucleic acid hybridization, and enzyme-linked immunosorbent assays (ELISA). These tests are used to detect the presence of specific genetic material in a sample, which can be used to identify the presence of a particular infectious agent.
Some companies in the NAT Screening market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. Show Less Read more